Resultados de procura - Gert Scheper

Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial por Veronica V. Rezelj, Fred Paddenburg, Marie Enajite Diegbe, Julius Nangosyah, Emil C. Reisinger, Weihong Hu, Carla Truyers, Gert Scheper, Mathieu Le Gars, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Hanneke Schuitemaker, Javier Ruiz-Guiñazú

Ligazón do recurso

An Ad26‐MVA‐BN‐based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections por Selina Khan, Satish Boedhoe, Miranda Baert, Jan Serroyen, Thierry Verbinnen, Ariane Volkmann, Markus Kalla, Katrin Weidner, Mathieu Le Gars, Jerry Sadoff, Michal Sarnecki, Jort Vellinga, Jerome Custers, Gert Scheper, Hanneke Schuitemaker, Roland Zahn

Ligazón do recurso

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised co... por Gabriela Tapia-Calle, Gloria Aguilar, Nathalie Vaissiere, Carla Truyers, Pedro Ylisastigui, Erik Buntinx, Mathieu Le Gars, Frank Struyf, Gert Scheper, Macaya Douoguih, Javier Ruiz-Guiñazú, Robert Patrizi, Wai Ling, Sanne de Ridder, Marit de Groot, Maria Grazia Pau, Gerald Weidinger, Srividya Pradeep, Nadine Salisch, Sophie Cambre

Ligazón do recurso